Search research articles
Contact Us
Filters
Showing results (521-530 of 636) with videos related to
Page
of 64
Sort By:
Current Controlled Trials in Cardiovascular Medicine
|
January 25, 2002
Systematic adjudication of myocardial infarction end-points in an international clinical trial
Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, et al.
Current Controlled Trials in Cardiovascular Medicine
|
January 25, 2002
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study
Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
December 2, 2006
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal
Warren J Cantor, Kenneth W Mahaffey, Zhen Huang, et al.
Blood Cells, Molecules & Diseases
|
July 30, 2018
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial
Pierluigi Tricoci, Megan Neely, Michael J Whitley, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
The American Journal of Cardiology
|
August 23, 2020
Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF)
Malini Madhavan, DaJuanicia N Holmes, Jonathan P Piccini, et al.
American Heart Journal
|
January 29, 2022
The ENHANCE-AF clinical trial to evaluate an atrial fibrillation shared decision-making pathway: Rationale and study design
Tina Baykaner, Krishna Pundi, Bryant Lin, et al.
American Heart Journal
|
August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
John L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
American Heart Journal
|
December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
Ashish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International
|
December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Page
of 64
Search research articles
Search
Showing results (521-530 of 636) with videos related to
Sort By:
Page
of 64
Current Controlled Trials in Cardiovascular Medicine
|
January 25, 2002
Systematic adjudication of myocardial infarction end-points in an international clinical trial
Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, et al.
Current Controlled Trials in Cardiovascular Medicine
|
January 25, 2002
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study
Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
December 2, 2006
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal
Warren J Cantor, Kenneth W Mahaffey, Zhen Huang, et al.
Blood Cells, Molecules & Diseases
|
July 30, 2018
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial
Pierluigi Tricoci, Megan Neely, Michael J Whitley, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
The American Journal of Cardiology
|
August 23, 2020
Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF)
Malini Madhavan, DaJuanicia N Holmes, Jonathan P Piccini, et al.
American Heart Journal
|
January 29, 2022
The ENHANCE-AF clinical trial to evaluate an atrial fibrillation shared decision-making pathway: Rationale and study design
Tina Baykaner, Krishna Pundi, Bryant Lin, et al.
American Heart Journal
|
August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
John L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
American Heart Journal
|
December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
Ashish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International
|
December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Page
of 64